Purpose of Review: To provide an economic context within which to consider treatment options for benign prostatic hyperplasia (BPH). To this end, this review provides a comparison of the costs of combination medical therapy, operative treatment, and office-based therapies for BPH from a payer perspective. Recent Findings: Analysis of Medicare charges from the authors’ institution, as well as local retail costs of medication, demonstrated a wide range in costs of commonly used BPH treatments. In this study, interventions for BPH reached cost equivalence with combination medical therapy within 6 months to 8 years. Summary: A myriad of options for managing men with symptomatic BPH exist. It is prudent not only to consider surgeon preference and patient-specific factors when selecting a treatment but also to understand the economic impact different BPH therapies confer.
CITATION STYLE
DeWitt-Foy, M. E., Gill, B. C., & Ulchaker, J. C. (2019, August 1). Cost Comparison of Benign Prostatic Hyperplasia Treatment Options. Current Urology Reports. Current Medicine Group LLC 1. https://doi.org/10.1007/s11934-019-0907-3
Mendeley helps you to discover research relevant for your work.